<DOC>
	<DOCNO>NCT02828254</DOCNO>
	<brief_summary>The purpose study To evaluate safety efficacy PRI-724 administration patient cirrhosis due hepatitis C 12-month follow-up .</brief_summary>
	<brief_title>A Follow-up Evaluation Study PRI-724-1101</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>1 . Having administer PRI724 Study 1101 confirm meet inclusion criterion meet exclusion criterion consent participate study . 2 . Having provide voluntary write consent participation study . 1 . Patients pregnant may pregnant , desire become pregnant may pregnant clinical study [ exclude patient undergone sterilization procedure postmenopausal patient ( amenorrhea without medical reason continue 12 month ) , patient nurse . 2 . Patients consent practice birth control clinical study ( include male patient ) . 3 . Patients serious allergy contrast medium history thereof . 4 . Patients history drug alcohol addiction within five year time provide write consent history drug alcohol abuse within past one year . 5 . Patients contraindicate liver biopsy . However , criterion apply patient turn contraindicated liver biopsy administer PRI724 Study 1101 . 6 . Patients participate another clinical trial , except PRI7241101 trial , within 30 day time provide write consent . 7 . Patients discontinue administration PRI724 Study 1101 due death reason become lose followup . 8 . Other , point Study 1101 complete ( discontinue ) , patient judge inappropriate inclusion study investigator reason presence serious pathological condition .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>